User login
Key clinical point: The 3-year bimekizumab treatment was well tolerated and effective in reducing the signs and symptoms of psoriatic arthritis (PsA).
Major finding: By week 152, 89.3% of patients had reported ≥1 treatment-emergent adverse event (TEAE), with serious TEAE being reported by 10.7% of patients. At least 20% improvement in American College of Rheumatology score was maintained by 64.1% of patients at week 152 compared with 72.3% of patients at week 48.
Study details: Findings are 3-year results from the phase 2b BE ACTIVE trial including 206 adults with active PsA who were randomly assigned to receive bimekizumab or placebo for 48 weeks, of which 184 patients were enrolled in the open-label extension phase for a further 104 weeks of treatment.
Disclosures: This study was supported by UCB Pharma. Four authors declared being employees of UCB Pharma and shareholders of UCB Pharma or GlaxoSmithKline. The other authors reported ties with various sources.
Source: Coates LC et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: 3-year results from a phase 2b randomized controlled trial and its open-label extension study. Arthritis Rheumatol. 2022 (Jul 13). Doi: 10.1002/art.42280
Key clinical point: The 3-year bimekizumab treatment was well tolerated and effective in reducing the signs and symptoms of psoriatic arthritis (PsA).
Major finding: By week 152, 89.3% of patients had reported ≥1 treatment-emergent adverse event (TEAE), with serious TEAE being reported by 10.7% of patients. At least 20% improvement in American College of Rheumatology score was maintained by 64.1% of patients at week 152 compared with 72.3% of patients at week 48.
Study details: Findings are 3-year results from the phase 2b BE ACTIVE trial including 206 adults with active PsA who were randomly assigned to receive bimekizumab or placebo for 48 weeks, of which 184 patients were enrolled in the open-label extension phase for a further 104 weeks of treatment.
Disclosures: This study was supported by UCB Pharma. Four authors declared being employees of UCB Pharma and shareholders of UCB Pharma or GlaxoSmithKline. The other authors reported ties with various sources.
Source: Coates LC et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: 3-year results from a phase 2b randomized controlled trial and its open-label extension study. Arthritis Rheumatol. 2022 (Jul 13). Doi: 10.1002/art.42280
Key clinical point: The 3-year bimekizumab treatment was well tolerated and effective in reducing the signs and symptoms of psoriatic arthritis (PsA).
Major finding: By week 152, 89.3% of patients had reported ≥1 treatment-emergent adverse event (TEAE), with serious TEAE being reported by 10.7% of patients. At least 20% improvement in American College of Rheumatology score was maintained by 64.1% of patients at week 152 compared with 72.3% of patients at week 48.
Study details: Findings are 3-year results from the phase 2b BE ACTIVE trial including 206 adults with active PsA who were randomly assigned to receive bimekizumab or placebo for 48 weeks, of which 184 patients were enrolled in the open-label extension phase for a further 104 weeks of treatment.
Disclosures: This study was supported by UCB Pharma. Four authors declared being employees of UCB Pharma and shareholders of UCB Pharma or GlaxoSmithKline. The other authors reported ties with various sources.
Source: Coates LC et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: 3-year results from a phase 2b randomized controlled trial and its open-label extension study. Arthritis Rheumatol. 2022 (Jul 13). Doi: 10.1002/art.42280